ABCC1 and Familial prostate cancer: To determine whether pharmacological inhibition of ABCC1 can affect prostate cancer cell proliferation through blockade of the ABCC1-mediated LPI autocrine loop, a panel of prostate cancer cell lines (PC3, LNCaP and DU145), as well as an immortalised normal prostatic epithelial cell line (PNT2), were treated with the ABCC1 inhibitors Reversan (Figure 3A) and MK571 (Figure 3B) and cell numbers were assessed after 72 h.